🏥 Shree Hospitals — Department of Gynecologic Oncology | Mumbai
Cervical Cancer — Symptoms, Screening & HPV Vaccine in IndiaThe Complete Patient Guide — Prevention, Early Detection, and Cure
Post-Coital Bleeding | Pap Smear | Colposcopy | HPV Vaccine (CERVAVAC, Gardasil 9, Cervarix) | CIN | Stage-by-Stage Guide
★ Cervical Cancer Is Preventable. Detected Early — It Is Curable. Act Today. ★
1.25 Lakh
New cervical cancer cases in India every year — 25% of global burden
99.7%
Of all cervical cancers caused by persistent HPV infection — a preventable cause
>90%
5-year survival rate for Stage I cervical cancer detected early
₹2,000
CERVAVAC dose cost — India's most affordable HPV vaccine
⭐ Key Facts at a Glance — Cervical Cancer, Screening & HPV Vaccine
India's Burden
Cervical cancer is the second most common cancer in Indian women — ~1.25 lakh new cases and 75,000 deaths every year. India accounts for approximately 25% of global cervical cancer deaths
Root Cause
Nearly 99.7% of all cervical cancers are caused by persistent infection with high-risk Human Papillomavirus (HPV) — primarily types 16 and 18. HPV is transmitted through sexual contact and is extremely common
#1 Early Warning Sign
Post-coital bleeding (bleeding after sexual intercourse) is the single most important early warning symptom of cervical cancer — present in approximately 70–80% of women at diagnosis. Any episode requires urgent evaluation.
It Is Preventable
The HPV vaccine (Gardasil 9, Cervarix, CERVAVAC) prevents infection with HPV types responsible for 70–90% of cervical cancers. Combined with regular Pap smear + HPV co-testing every 3–5 years, cervical cancer is the most preventable of all gynaecological cancers.
Survival by Stage
Stage I cervical cancer: >90% 5-year survival. Stage IV: below 15%. The difference is almost entirely determined by when the cancer is detected. This is why screening and early symptom recognition are so critical.
CERVAVAC — India's Own Vaccine
India's first indigenously developed HPV vaccine by the Serum Institute of India. Available at approximately ₹2,000–2,500 per dose — making the 2-dose schedule accessible to a far wider population than imported vaccines.
Screening Fact
Cervical cancer in India is largely a disease of women who have never been screened. A single Pap smear in a lifetime reduces cervical cancer mortality by over 25%. Regular screening (3–5 yearly) reduces it by more than 80%.
Contact Us
Dr. Jay Mehta & Team | Shree Hospitals, Mumbai
+91-9920914115 | 18002684000 | Online consultations available for all India
+91-9920914115 | 18002684000 | Online consultations available for all India
Of all the cancers that affect women, cervical cancer occupies a unique and profoundly important position: it is almost entirely preventable. Unlike most cancers, where the causes are complex and the prevention strategies are indirect, cervical cancer has a single, well-characterised cause (HPV infection), a reliable, accessible early detection test (the Pap smear), and a safe, highly effective vaccine (Gardasil 9, Cervarix, and CERVAVAC) that prevents the cancer from developing in the first place.
Yet despite all of this, India bears one of the highest cervical cancer burdens in the world — approximately 1.25 lakh new cases and 75,000 deaths every year. India alone accounts for approximately 25% of the world's cervical cancer deaths. This is not a reflection of the disease's inherent danger — it is a reflection of the gap between what is possible through prevention and early detection, and what is currently being achieved through awareness, vaccination, and screening uptake.
The Most Dangerous Misconception in Cervical Cancer Awareness
The cervix has no pain receptors on its surface. A tumour can grow on the cervix to a considerable size without causing any pain whatsoever. Pain only develops when the tumour has grown beyond the cervix and begun to invade the parametrial tissues and pelvic nerves. Waiting for pain before seeking evaluation is waiting too long. Post-coital bleeding is the signal to act — not pelvic pain.
Cervical Cancer — The Prevention, Detection and Treatment Journey
The journey from HPV vaccination and regular Pap smear screening through to early detection, colposcopy, CIN treatment, and cure. At Shree Hospitals, Dr. Jay Mehta & Team provide the complete continuum of cervical cancer care — from Pap smear and colposcopy through to radical hysterectomy, brachytherapy, and survivorship.
Part 1 — What Are the First Signs of Cervical Cancer?
1What Is the Very First Symptom of Cervical Cancer — What Should Every Woman Know?
Direct Answer: The very first and most important symptom of cervical cancer is post-coital bleeding (PCB) — vaginal bleeding during or immediately after sexual intercourse. Present in approximately 70–80% of women at diagnosis. It is painless, often dismissed, and occurs before the cancer has spread. Do not dismiss it. Any episode of PCB requires urgent cervical examination and Pap smear.
Cervical cancer is, in many ways, the gynaecological cancer that gives women the best chance of early detection — because its earliest symptom, post-coital bleeding, is specific, noticeable, and occurs before the cancer has spread. The tragedy is that this symptom is dismissed far too often. Women attribute it to friction, dryness, their contraceptive pill, or a previous smear having been recent and normal. This dismissal is the critical point of failure that allows early cervical cancer to progress to advanced disease.
Table 1: First Signs of Cervical Cancer — Early Presentation vs Later Progression
← Scroll to view full table →
| Symptom | How It Appears in Early Cervical Cancer (Stage I–IIA) | How It Worsens in Advanced Disease (Stage IIB–IV) |
|---|---|---|
| Post-Coital Bleeding (Bleeding after Sex) | The most characteristic early symptom. A small amount of blood or spotting after intercourse — often dismissed as 'the partner was rough' or 'cervical erosion.' May occur with first or subsequent sexual encounters after the cancer develops. Often completely painless. | Less relevant as cancer advances — frank vaginal bleeding occurs spontaneously, not only after intercourse. Bleeding becomes heavier, more frequent, and harder to attribute to a specific trigger. |
| Intermenstrual Bleeding (Between Periods) | Light spotting or bleeding between periods — often attributed to hormonal fluctuation, fibroids, or 'missed period.' May be intermittent and easy to dismiss. Consistently present but variable in amount. | Heavier, more persistent bleeding that occurs without relation to the menstrual cycle. Eventually merges with post-coital bleeding and spontaneous bleeding. |
| Vaginal Discharge | Thin, watery or slightly mucoid discharge — often persistent and slightly unusual in character. May have a faint, unfamiliar odour. Easily attributed to vaginal infection. Often the symptom women notice before bleeding begins. | Offensive, foul-smelling discharge as the tumour necrotises (breaks down). May become blood-tinged or frankly bloody. Quantity increases. Often mistaken for recurrent vaginal infection — repeated antibiotic courses without resolution. |
| Pelvic Discomfort / Pain | Minimal or ABSENT in early cervical cancer. Some women notice a vague heaviness or dragging sensation in the pelvis — not severe enough to seek attention. Pain is NOT a feature of early cervical cancer. | Progressive pelvic pain as the tumour infiltrates the parametria, pelvic sidewall, and eventually pelvic nerves. Classic 'sciatic' pain radiating down one or both legs suggests pelvic sidewall involvement (Stage IIIB). |
| Dyspareunia (Pain during Intercourse) | Mild, new discomfort during deep penetration — easily attributed to vaginal dryness, position, or 'normal variation.' Not severe enough to stop sexual activity initially. | Significant deep pain during intercourse as the tumour invades adjacent tissues. Dyspareunia with bleeding is a combination that must always trigger cervical examination. |
| Urinary Symptoms | Usually absent in early disease. Occasional mild urinary frequency if the tumour lies anteriorly and presses on the bladder base. | Haematuria (blood in urine) from bladder invasion (Stage IVA). Ureteric obstruction causes hydronephrosis — presenting as flank pain. Vesicovaginal fistula (abnormal connection between bladder and vagina) in very advanced disease. |
| Constitutional Symptoms | None — early cervical cancer produces no weight loss, fatigue, or anaemia. | Anaemia from chronic blood loss causes fatigue, breathlessness, and pallor. Unintentional weight loss. Leg swelling from lymphoedema. Cachexia in very advanced disease. |
Part 2 — Symptoms of Cervical Cancer by Stage
2What Are the Symptoms and Survival Rates at Each Stage of Cervical Cancer?
Direct Answer: Stage IA cervical cancer is typically completely asymptomatic — found only through Pap smear. Stage IB produces only post-coital bleeding and mild discharge, with 5-year survival of 88–95%. By Stage IIB, pelvic pain begins. By Stage IV, survival falls below 15–22%. Every stage difference matters enormously — which is why acting on early, mild symptoms is the most important thing any woman can do.
The most important message: Stage I cervical cancer is often completely asymptomatic (Stage IA) or produces only post-coital bleeding and mild discharge (Stage IB). A woman who is regularly screened or who responds promptly to PCB will be diagnosed at Stage I — when cure rates exceed 90%. A woman who dismisses PCB for months will present at Stage IIB or later — when treatment is more complex and outcomes less certain.
Table 2: Cervical Cancer Symptoms by FIGO Stage — Symptoms, Treatment, and Survival
← Scroll to view full table →
| Stage | Disease Extent | Typical Symptoms | Standard Treatment | 5-Year Survival |
|---|---|---|---|---|
| IA | Microscopic invasion only — depth <5mm, width <7mm | Typically NONE — Stage IA is found only through Pap smear and colposcopic biopsy. No symptoms whatsoever in most cases. Clinically invisible to the naked eye. | Pap smear → Colposcopy → Cone biopsy or LLETZ (depending on depth) | 93–99% |
| IB1 | Visible tumour ≤2cm confined to cervix | Post-coital bleeding is the most common symptom. Slight intermenstrual spotting. May notice increased watery discharge. Pelvic pain is NOT present. | Radical hysterectomy + pelvic lymphadenectomy (laparoscopic or open) OR radiotherapy alone | 88–95% |
| IB2 | Visible tumour 2–4cm confined to cervix | Post-coital bleeding, intermenstrual bleeding, watery or blood-tinged discharge. Pelvic examination reveals a palpable cervical mass. Still no parametrial involvement. | Radical hysterectomy + lymphadenectomy OR concurrent chemoradiotherapy (CCRT) | 75–85% |
| IB3 | Tumour >4cm confined to cervix | Prominent bleeding — post-coital and intermenstrual. Offensive discharge beginning. Bulk from large tumour may cause pelvic pressure. Cervix replaced by bulky, friable (easily bleeding) tumour on examination. | Concurrent CCRT (preferred for bulky IB3) OR radical hysterectomy at specialist centres | 65–75% |
| IIA | Extension to upper vagina — no parametrial invasion | Similar to IB symptoms — bleeding, discharge. Vaginal involvement may cause bleeding from the vaginal extension. | Concurrent CCRT OR surgery at specialist centres | 60–74% |
| IIB | Parametrial invasion — NOT reaching pelvic sidewall | Onset of pelvic pain — dull ache or discomfort in the lower pelvic region. Persistent bleeding and offensive discharge. Pelvic examination reveals induration (hardening) in the parametria. | Concurrent CCRT: external beam radiotherapy + weekly cisplatin + intracavitary brachytherapy | 58–65% |
| IIIA–B | Lower vaginal and/or pelvic sidewall involvement | Significant pelvic pain, possibly radiating down the leg (sciatic distribution). Persistent heavy bleeding. Leg oedema begins as lymphatics are compressed. | Concurrent CCRT + possible extended field radiation to para-aortic nodes | 32–40% |
| IIIC | Pelvic and/or para-aortic lymph node involvement | Lymph node involvement adds systemic symptoms — leg swelling, back pain, fatigue. Heavy bleeding. Significant pelvic pressure. Anaemia becoming clinically apparent. | Concurrent CCRT with extended field radiation. Immunotherapy (pembrolizumab) in recurrent disease. | 32–57% |
| IVA–B | Bladder/bowel invasion; distant metastases | Haematuria (blood in urine), rectal bleeding, severe pelvic pain, leg swelling, breathlessness (lung metastases), bone pain. Profound anaemia. | Palliative CCRT, systemic chemotherapy, pembrolizumab + chemotherapy (KEYNOTE-826). Supportive care integration essential. | <10–22% |
Part 3 — Risk Factors for Cervical Cancer
3What Raises the Risk of Cervical Cancer — and What Protects Against It?
Direct Answer: The #1 risk factor is persistent high-risk HPV infection — the direct cause of 99.7% of all cervical cancers. The #1 preventable risk is never having been screened — fewer than 30% of eligible Indian women have ever had a Pap smear. The two most powerful protective factors are: the HPV vaccine (90% cancer prevention potential) and regular Pap smear + HPV co-testing (80%+ mortality reduction).
Table 3: Risk Factors for Cervical Cancer — What Raises Your Risk and What Protects You
← Scroll to view full table →
| Risk Factor | Risk Level | Why It Matters |
|---|---|---|
| Persistent high-risk HPV infection (Types 16, 18, 31, 33, 45, 52, 58) | VERY HIGH — Causal | HPV is not a risk factor — it is the direct cause. Without persistent HPV infection, cervical cancer essentially cannot develop. Types 16 and 18 alone cause 70% of cervical cancers. HPV vaccine and Pap smear screening together virtually eliminate cervical cancer. |
| No or infrequent cervical screening (No Pap smear in >3–5 years) | VERY HIGH — Most important preventable risk | India has a very low cervical screening uptake — fewer than 30% of eligible women have ever had a Pap smear. Women who are never screened are 10 times more likely to develop invasive cervical cancer than those who are regularly screened. |
| Early sexual debut (before age 16) | MODERATE | The transformation zone is largest and most HPV-vulnerable in young women. Earlier sexual activity increases the duration and probability of HPV exposure. |
| Multiple sexual partners (self or partner) | MODERATE | Cumulative HPV exposure increases with number of partners. A woman with a single lifetime partner can still acquire HPV if her partner has had multiple partners. |
| Smoking (current or former) | MODERATE — 2× increased risk | Tobacco carcinogens accumulate in cervical mucus and damage local cervical immunity, impairing HPV clearance. Smoking doubles the risk of squamous cell cervical cancer and accelerates CIN progression. |
| Immunosuppression (HIV infection, transplant, long-term steroids) | HIGH — 5–10× increased risk | Impaired immune function prevents clearance of HPV infection. HIV-positive women have a dramatically higher risk and require annual cervical screening. Cervical cancer is an AIDS-defining illness. |
| Long-term oral contraceptive use (>5 years) | MILD — 1.5–2× modest increase | OCP use is associated with a modest increase in cervical cancer risk — possibly through direct hormonal effects on HPV persistence. Risk declines after stopping the pill and returns to baseline by 10 years. |
| Low socioeconomic status / Limited healthcare access | HIGH — Strong contextual risk in India | Low income, limited access to screening, cultural barriers to pelvic examination, and low HPV awareness collectively drive the high cervical cancer burden in India's lower-income populations. |
| HPV Vaccination (Gardasil 9, Cervarix, CERVAVAC) | HIGHLY PROTECTIVE — 90% cancer prevention potential | The most powerful tool in cervical cancer prevention. Prevents infection with the HPV types responsible for 70–90% of cervical cancers. Most effective before sexual debut but beneficial up to age 45. |
| Regular Pap smear + HPV co-testing (Every 3–5 years from age 21/25) | HIGHLY PROTECTIVE — 80%+ mortality reduction | Detects CIN at 100% curable stage. Even a single Pap smear in a lifetime reduces mortality meaningfully. Regular screening virtually eliminates cervical cancer mortality in compliant populations. |
Have you had a Pap smear in the last 3–5 years?
If not — book your cervical screening with Dr. Jay Mehta & Team at Shree Hospitals today. It takes less than 10 minutes and could save your life.
Part 4 — Is Post-Coital Bleeding Always Cervical Cancer?
4Post-Coital Bleeding — What Causes It and When Is It Cervical Cancer?
Direct Answer: Post-coital bleeding (PCB) is NOT always cervical cancer. The most common cause in young women is cervical ectropion — a completely benign condition. However, PCB IS the most characteristic early symptom of cervical cancer. The clinical obligation is absolute: EVERY episode of PCB requires a speculum examination of the cervix and Pap smear — regardless of age, contraceptive use, or recent smear result.
The Dangerous Myth of the Contraceptive Pill
One of the most clinically damaging misconceptions in women's health is that the oral contraceptive pill (OCP) causes post-coital bleeding. This is factually incorrect. The OCP does not cause post-coital bleeding. When a woman on the OCP presents with post-coital bleeding and is told 'it's just from the pill' without a cervical examination, this is a clinical error with potentially serious consequences. Any woman who has been told this should request a cervical examination and Pap smear at their next available appointment.
Table 4: Post-Coital Bleeding — All Causes, Their Nature, and Required Clinical Action
← Scroll to view full table →
| Cause of Post-Coital Bleeding | Nature and Frequency | Clinical Significance and Required Action |
|---|---|---|
| Cervical Ectropion (Cervical Erosion) | BENIGN — Very Common (30–40% of reproductive-age women) | The glandular cells of the endocervical canal extend onto the outer cervix — forming a velvety, red area that bleeds easily on contact. NOT an erosion or damage. Very common in young women, during pregnancy, and in women on the contraceptive pill. Confirmed by speculum examination. A Pap smear is always performed to confirm there is no dysplasia on the ectropion. |
| Cervicitis (Cervical Infection) | BENIGN — Treatable (chlamydia, gonorrhoea, trichomonas) | Infection causes inflammation and friability of the cervical epithelium, producing contact bleeding. Chlamydia is the most common cause — and is often asymptomatic except for discharge and PCB. NAAT swabs for STIs are mandatory in all women with PCB. Treated with appropriate antibiotics. |
| Cervical Polyp | BENIGN — Low Cancer Risk (1–3%) | Benign growth arising from the endocervical canal. Visible on speculum examination. Removed by avulsion (twisting off) or diathermy in a clinic setting. Histological examination is always performed — malignant degeneration occurs in approximately 1–3% of polyps, higher in post-menopausal women. Never discard a polyp without sending it for histology. |
| Vaginal Atrophy (Post-menopausal) | BENIGN — Common after menopause | Oestrogen deficiency causes thinning and fragility of the vaginal and cervical epithelium. Minimal trauma during intercourse causes contact bleeding. Treated with topical vaginal oestrogen. Important: even in post-menopausal atrophic vaginitis, a Pap smear must be performed to exclude concurrent cervical or endometrial pathology before attributing bleeding to atrophy alone. |
| Cervical Dysplasia (CIN 1, 2, 3) | PRE-CANCEROUS — Requires Colposcopy | HPV-related precancerous changes of the transformation zone can produce contact bleeding. The abnormal epithelium is more fragile than normal. CIN 1 carries low cancer risk; CIN 2–3 require treatment (LLETZ). Any PCB with an abnormal-appearing cervix requires urgent colposcopy — do not wait for smear results before referring for colposcopy if a lesion is visible. |
| AIS (Adenocarcinoma In Situ) | PRE-CANCEROUS — Urgent Specialist Referral | Glandular pre-invasive cancer of the endocervical canal. May present with PCB or unusual mucoid discharge. Invisible on colposcopy in many cases (endocervical location). Detected by Pap smear (AGC or AIS on cytology) or by biopsy. Requires cone biopsy. Concurrent invasive cancer present in up to 13% of cases. |
| Cervical Cancer (Squamous Cell Carcinoma or Adenocarcinoma) | CANCER — Urgent Evaluation Required | PCB is the cardinal early symptom of cervical cancer — present in 70–80% of women at diagnosis. The tumour is friable, vascular, and bleeds on minimal contact. A visible lesion on the cervix during speculum examination is an indication for immediate biopsy — without waiting for Pap smear results. Do not reassure a woman with a visible cervical lesion and PCB until a biopsy has been taken. |
Part 5 — The Role of Pap Smear and Colposcopy in Early Diagnosis
5What Does My Pap Smear Result Mean — A Complete Plain Language Guide
Direct Answer: A normal cytology + HPV Negative result is the most reassuring — return for routine screening in 5 years. ASCUS requires HPV reflex testing. LSIL (CIN 1) requires colposcopy. HSIL (CIN 2–3) requires urgent colposcopy + LLETZ. AGC (Atypical Glandular Cells) requires urgent specialist evaluation. A positive for cancer result requires immediate biopsy and oncology referral — do not delay.
The Pap smear (cervical cytology test) combined with HPV co-testing is the most powerful cancer prevention tool in all of women's health. Regular cervical screening can reduce cervical cancer mortality by over 80% in compliant populations. In India, cervical cancer screening uptake is critically low — estimated at fewer than 30% of eligible women having ever undergone a Pap smear. This is the primary driver of India's enormous cervical cancer burden.
Table 5: Pap Smear and HPV Test Results — A Complete Plain Language Guide
← Scroll to view full table →
| Pap Smear / HPV Co-test Result | Risk Level and Action | What It Means and Next Steps |
|---|---|---|
| Normal cytology + HPV Negative | LOW RISK — 5-year routine recall | The most reassuring possible result. Cervical cancer risk is extremely low. Recall for next routine smear in 5 years (co-testing protocol) or 3 years (cytology only). No further action needed. |
| Normal cytology + HPV Positive (High-risk types other than 16/18) | INTERMEDIATE — Repeat co-test in 12 months | HPV present but cells look normal. Most infections clear in 12 months. Repeat HPV test in 12 months — if still positive, refer for colposcopy. If negative, return to routine screening. |
| Normal cytology + HPV 16 or HPV 18 Positive | MODERATE–HIGH — Refer for Colposcopy | Even with normal cells, HPV 16 and 18 are high enough risk that colposcopy referral is recommended immediately — because CIN 3 or AIS may be present in the endocervical canal beyond cytological detection. |
| ASCUS (Atypical Squamous Cells of Uncertain Significance) | INTERMEDIATE — HPV reflex testing | Mildly atypical cells. If HPV negative: repeat smear in 12 months. If HPV positive: refer for colposcopy. Most ASCUS with HPV negative resolves spontaneously. |
| LSIL (Low-Grade SIL — CIN 1) | LOW–MODERATE — Colposcopy recommended | Mild dysplasia consistent with active HPV infection. Colposcopy with biopsy to confirm grade. Most CIN 1 regresses in 2 years without treatment. Active surveillance with repeat smear at 12 months — LLETZ if persistent at 24 months. |
| HSIL (High-Grade SIL — CIN 2–3) | HIGH — Urgent Colposcopy + LLETZ | Significant precancerous change. CIN 3 will progress to cancer if untreated. Refer for urgent colposcopy and directed biopsy. LLETZ (outpatient procedure, 15 minutes, local anaesthetic) achieves >95% cure. 10-year surveillance smears post-LLETZ. |
| AGC (Atypical Glandular Cells) | HIGH — Urgent specialist evaluation | Glandular abnormality — affects the glandular cells (endocervical or endometrial origin). Higher risk of significant pathology including AIS or invasive cancer. Requires colposcopy + endocervical sampling + endometrial biopsy. Urgent referral to Gynecologic Oncologist. |
| AIS (Adenocarcinoma In Situ) | VERY HIGH — Urgent specialist referral | Pre-invasive glandular cancer. Cone biopsy (not just LLETZ) required for complete assessment. Concurrent invasive cancer present in ~13% of cases. Hysterectomy recommended for women who have completed their family. |
| Suspicious for / Positive for Cancer | URGENT — Immediate biopsy and oncology referral | Cells consistent with invasive cancer. If a visible cervical lesion is present, biopsy it immediately — do not wait for smear results. Staging MRI and CT arranged urgently. Treatment at a specialist Gynecologic Oncology centre. |
6What Is Colposcopy and What Do the CIN Findings Mean?
Direct Answer: Colposcopy is a diagnostic examination of the cervix performed when a Pap smear is abnormal or when a cervical lesion needs direct assessment. A lighted magnifying instrument (colposcope) provides a magnified (×10–40) view of the cervical surface. The cervix is painted with acetic acid (which makes abnormal areas appear white) and Lugol's iodine. Abnormal areas are biopsied under direct visualisation. CIN 1 is usually managed with surveillance; CIN 2–3 requires LLETZ treatment.
Table 6: Colposcopy Findings and CIN Classification — What Each Finding Means and Requires
← Scroll to view full table →
| Colposcopy Finding | Colposcopic Appearance | Pathological Meaning | Management and What to Expect |
|---|---|---|---|
| Normal Colposcopy | Transformation zone fully visualised — no acetowhite areas, no abnormal vessels | Normal squamous and glandular epithelium with no HPV effect | Routine surveillance. Pap smear at 12 months if cytology was abnormal. Return to routine screening if smear at 12 months is normal. |
| CIN 1 (Low-Grade) | Thin, faint acetowhite areas with regular borders. Satisfactory colposcopy. | Mild dysplasia — outer one-third of epithelium. High rate of spontaneous regression (60%). | Active surveillance — repeat smear at 12 months. LLETZ if CIN 1 persists for 24 months or if patient preference for treatment. |
| CIN 2 (Moderate) | Dense acetowhite change. Irregular mosaic and punctation patterns on colposcopy. | Moderate dysplasia — outer two-thirds of epithelium involved. | LLETZ (Large Loop Excision of Transformation Zone) — outpatient, local anaesthetic, 15 minutes. Histology to confirm diagnosis and clear margins. Surveillance smear at 6 months, 12 months, then 3-yearly for 10 years. |
| CIN 3 (Severe / Carcinoma In Situ) | Coarse punctation and mosaic. Dense acetowhite. Possible abnormal vessels. | Full-thickness epithelial dysplasia — but basement membrane intact (not yet invasive). | LLETZ is standard treatment — must achieve clear margins. If margins involved: re-excision or cone biopsy. Hysterectomy for recurrent CIN 3 in women who have completed their family. |
| AIS (Adenocarcinoma In Situ) | Colposcopy may appear normal or show atypical changes — AIS is often in the endocervical canal beyond direct visualisation | Pre-invasive glandular cancer — above transformation zone in endocervical canal | Cone biopsy required (not LLETZ alone). Clear endocervical margins essential. Hysterectomy strongly recommended for women who have completed their family — 'skip lesion' nature of AIS means simple LLETZ often misses disease. |
| Stage IA1 Microinvasive Cancer | Colposcopy shows abnormal vessels and coarse acetowhite change | Invasion <3mm depth, <7mm width — microscopic only | Cone biopsy with clear margins may be sufficient for fertility-preserving treatment. Simple hysterectomy for women who have completed family. >99% 5-year survival. |
| Macroscopic Cancer (Stage IB+) | Visible tumour — friable, bleeding, irregular. Colposcopy confirms cancer; staging then required. | Invasion beyond microinvasion — visible to the naked eye on speculum examination | BIOPSY IMMEDIATELY — do not wait for smear results. Urgent staging MRI and CT. Referral to Gynecologic Oncology team at Shree Hospitals. Radical hysterectomy or CCRT depending on stage. |
Part 6 — The HPV Vaccine: Does It Work? Which One? How Much Does It Cost?
7Does the HPV Vaccine Really Work — How Effective Is It?
Direct Answer: Yes — the HPV vaccine is one of the most effective cancer prevention vaccines ever developed. Clinical trial data shows 97–100% efficacy against CIN 2+ (precancerous changes) caused by the vaccine HPV types. Population data from Australia — which introduced universal HPV vaccination for girls in 2007 — shows a 77% reduction in high-grade cervical lesions in women aged 20–24. Australia is projected to be the first country to eliminate cervical cancer as a public health problem by the mid-2030s.
The vaccine works by triggering the immune system to produce antibodies against specific HPV proteins — so that if the vaccinated person encounters HPV in the future, these pre-formed antibodies neutralise the virus before it can establish an infection. The vaccine does not contain live virus and cannot cause HPV infection or cervical cancer. It is safe, well-tolerated, and has been given to hundreds of millions of people worldwide.
Critical — The Vaccine Does NOT Replace Pap Smear Screening
Even vaccinated women must continue regular cervical screening from the appropriate age. The vaccine covers 70–90% of cervical cancer-causing HPV types but not all. Vaccination + regular Pap smear + HPV co-testing is the complete prevention strategy. Neither alone is sufficient.
Table 7: HPV Vaccines Available in India — Complete Comparison (Types, Schedule, Costs)
← Scroll to view full table →
| Vaccine Name / Manufacturer | Type & HPV Types Covered | Approved Age Range | Dosing Schedule | Approximate Cost in India |
|---|---|---|---|---|
| Gardasil 9 (MSD / Merck Sharp & Dohme) | 9-Valent HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 | 9–45 years (male and female) | 9–14 yrs: 2-dose (0, 6 months) 15+ yrs: 3-dose (0, 2, 6 months) | ₹8,500–10,000 per dose 2-dose total: ₹17,000–20,000 3-dose total: ₹25,500–30,000 |
| Cervarix (GlaxoSmithKline — GSK) | 2-Valent HPV 16, 18 | 9–45 years (females only) | 9–14 yrs: 2-dose (0, 6 months) 15+ yrs: 3-dose (0, 1, 6 months) | ₹2,500–3,500 per dose 2-dose total: ₹5,000–7,000 3-dose total: ₹7,500–10,500 |
| CERVAVAC (Serum Institute of India — SII) India's Own Vaccine | 4-Valent (Indigenous) HPV 6, 11, 16, 18 | 9–26 years (females) | 9–14 yrs: 2-dose (0, 6 months) 15–26 yrs: 3-dose (0, 2, 6 months) | ₹2,000–2,500 per dose 2-dose total: ₹4,000–5,000 3-dose total: ₹6,000–7,500 Most affordable option — Made in India |
8What Is the HPV Vaccination Schedule — When Should My Daughter Get Vaccinated?
Direct Answer: Ages 9–14 is the optimal window — the 2-dose schedule (not 3 doses) is sufficient at this age, as immune response is strongest before HPV exposure (before sexual debut). Maximum protection: up to 90%+ against covered HPV types. Women up to age 45 can still benefit from vaccination against HPV types not yet acquired.
Table 8: HPV Vaccination Schedule by Age Group — Protocol and Recommendations
← Scroll to view full table →
| Age Group | Recommended Schedule | Recommended Vaccine | Key Considerations |
|---|---|---|---|
| 9–14 years (Optimal age — BEFORE sexual debut) | 2-dose schedule: Dose 1: Day 0 Dose 2: 6 months after Dose 1 | Any approved HPV vaccine. Gardasil 9 preferred for broadest coverage. CERVAVAC for cost-accessibility. | The MOST EFFECTIVE age group. The immune response to 2 doses at this age is as strong as 3 doses in older women. No booster currently recommended. Vaccinating before HPV exposure provides maximum protection — up to 90%+ protection against covered HPV types. |
| 15–26 years (High benefit — catch-up vaccination) | 3-dose schedule: Dose 1: Day 0 Dose 2: 1–2 months after Dose 1 Dose 3: 6 months after Dose 1 | All three vaccines approved in this age group. For Cervarix: 0, 1, 6 months For Gardasil 9 / CERVAVAC: 0, 2, 6 months | Still highly effective even if already sexually active — likely not yet exposed to all vaccine HPV types. Vaccination reduces risk of cervical disease from HPV types not yet acquired. Cost-effective in terms of cancer prevention per dose. |
| 27–45 years (Benefit exists — shared decision) | 3-dose schedule (same as above) | Gardasil 9 approved up to age 45. Cervarix approved up to age 45. CERVAVAC — approval status for this age group being reviewed. | Benefit is reduced compared to younger women because some prior HPV exposure has likely occurred. However, partial protection from unacquired types is still valuable. Women with new sexual partners or previously unvaccinated benefit most. |
| Immunocompromised women (HIV, transplant, steroids) | 3-dose schedule regardless of age | All approved vaccines — consult specialist for timing around immunosuppressive therapy | Immunocompromised women may have reduced vaccine immunogenicity but still benefit. HIV-positive women should be vaccinated — ideally when CD4 count >200. HPV vaccines are non-live and safe in immunocompromised patients. |
| Post-treatment for CIN or Cervical Cancer | As per age-appropriate schedule | Any approved vaccine per age group | Vaccination after CIN treatment reduces recurrence risk. Vaccination after cancer treatment: evidence supports benefit in reducing risk of second HPV-related events, though the primary cancer has already occurred. Discuss timing with treating oncologist at Shree Hospitals. |
Want to vaccinate your daughter or yourself against cervical cancer?
Book your HPV vaccination appointment at Shree Hospitals — available for all age groups. CERVAVAC, Gardasil 9, and Cervarix available.
Part 7 — Why Patients Travel Across India to Shree Hospitals for Cervical Cancer Treatment
9Why Do Women from Across India Choose Shree Hospitals for Cervical Cancer Treatment?
Direct Answer: Women travel from Gujarat, Rajasthan, Madhya Pradesh, Chhattisgarh, Andhra Pradesh, Karnataka, and beyond for several specific reasons: Dr. Jay Mehta's surgical expertise in radical hysterectomy and radical trachelectomy (fertility-preserving surgery); complete CCRT package (external beam radiotherapy + brachytherapy + concurrent cisplatin) under one roof; true Multidisciplinary Oncology Team; and Interventional Radiology + Tertiary ICU backup for complex cases.
Table 9: Why Patients Choose Dr. Jay Mehta and Shree Hospitals — Clinical Excellence Factors
← Scroll to view full table →
| Excellence Factor | Why This Matters for Your Cervical Cancer Care |
|---|---|
| Specialist Gynecologic Oncologist — Dr. Jay Mehta & Team | Dr. Jay Mehta is a dedicated Advanced Pelvic Surgeon with subspecialty training and extensive clinical experience in the surgical and medical management of all gynaecological cancers, including cervical cancer. His team also includes dedicated full-time MCH Gynec Cancer surgeons. For cervical cancer specifically, surgical expertise ranges from fertility-preserving cone biopsy and radical trachelectomy (removal of the cervix with preservation of the uterus in young women wishing to have children) to standard radical hysterectomy with pelvic lymphadenectomy and sentinel lymph node mapping. |
| Fertility-Preserving Surgery for Young Women with Cervical Cancer | For young women with early cervical cancer (Stage IA2–IB1 ≤2cm) who wish to preserve fertility, Dr. Jay Mehta performs radical trachelectomy — surgical removal of the cervix with preservation of the uterus, allowing future pregnancy. This highly specialised procedure — performed laparoscopically or with robotic assistance — removes the cancer completely while leaving the uterine body intact and reconnecting it to the upper vagina. Successful pregnancies after radical trachelectomy have been well-documented in medical literature. This procedure requires the experience and technical precision of a dedicated Gynecologic Oncologist — and is available at Shree Hospitals for appropriately selected patients. |
| True Multidisciplinary Oncology Team | Cervical cancer treatment requires seamless coordination between surgical, medical, and radiation oncology. At Shree Hospitals, every case of cervical cancer is discussed at a formal MDT meeting that includes: Gynecologic Oncologist and Oncosurgeon, Medical Oncologists who manage concurrent cisplatin chemotherapy protocols, Radiation Oncologists who plan and deliver external beam radiotherapy and intracavitary brachytherapy, specialist Radiologists, Pathologists, dedicated Gynecologic Oncology Nurses, and a Palliative Care team for holistic symptom management. This integrated team approach is what produces consistently superior outcomes. |
| Brachytherapy (Intracavitary Radiotherapy) Capability | For locally advanced cervical cancer (Stage IIB–IVA), concurrent chemoradiotherapy (CCRT) is the gold standard treatment. Brachytherapy provides the highest radiation dose directly to the cervical tumour while sparing adjacent bladder and rectum. It is an essential component of CCRT and significantly improves local control and survival rates. Not all hospitals are equipped with brachytherapy infrastructure. Shree Hospitals has a complete radiotherapy department including state-of-the-art brachytherapy capability — ensuring that every patient receives the complete gold-standard CCRT treatment protocol without needing to travel to multiple centres. |
| Interventional Radiology (IR) Support | Shree Hospitals has a dedicated Interventional Radiology department providing round-the-clock support. For cervical cancer patients specifically, IR provides: image-guided cervical and pelvic biopsy for tissue diagnosis; ureteric stenting for hydronephrosis caused by ureteric obstruction from advanced cervical cancer; nephrostomy (kidney drainage) for acute kidney failure from bilateral ureteric compression; embolisation of uterine artery or pelvic vessels for emergency control of severe haemorrhage from advanced cervical tumours; CT-guided lymph node biopsy for staging; and placement of vascular access devices (ports) for long-term chemotherapy administration. |
| Tertiary Level ICU and Anaesthesia Excellence | Radical hysterectomy for cervical cancer is major surgery requiring expert anaesthesia and post-operative critical care. Shree Hospitals' fully equipped, 24-hour consultant-staffed tertiary ICU ensures that every patient undergoing major cervical cancer surgery has access to the highest level of post-operative care — including advanced haemodynamic monitoring, ventilatory support, and immediate specialist availability. |
| Continuity of Care — From Diagnosis to Survivorship | Cancer treatment does not end with surgery or the completion of radiotherapy. Shree Hospitals provides a comprehensive, structured survivorship programme: follow-up every 3 months for the first 2 years; every 6 months for years 3–5; annual review thereafter; psychosocial support and sexual health counselling (radiation to the pelvis affects sexual function and vaginal health); physiotherapy for lymphoedema management; and telemedicine/online consultation for patients from other states who cannot travel to Mumbai for every follow-up. |
Consult Dr. Jay Mehta & Team — Gynecologic Oncology, Shree Hospitals
Cervical cancer is preventable. Detected early, it is curable. These are not hopeful statements — they are evidence-based facts. The tools exist: the Pap smear, the HPV vaccine, and specialist surgical and oncological care. For women from other states, online consultations allow initial case review before committing to travel. When the time comes for surgery or advanced treatment, our team will be ready for you.
Frequently Asked Questions — Cervical Cancer, Screening & HPV Vaccine in India
The very first symptom of cervical cancer — the one that most often leads to early diagnosis — is post-coital bleeding: vaginal bleeding that occurs during or immediately after sexual intercourse. This is present in approximately 70–80% of women with cervical cancer at the time of diagnosis and can occur even when the tumour is still small and confined to the cervix (Stage I — the most curable stage). Other early symptoms include: light intermenstrual bleeding (bleeding between periods, not related to the menstrual cycle); a persistent, slightly unusual vaginal discharge — often described as watery, thin, or mildly odorous; and mild dyspareunia (discomfort during deep intercourse). Critically — pelvic pain is NOT an early symptom of cervical cancer. When pain develops, it indicates that the cancer has already spread beyond the cervix to the parametria or pelvic sidewall (Stage IIB or beyond). The absence of pelvic pain does not mean the cancer is not there.
Yes — the HPV vaccine is one of the most effective cancer prevention vaccines ever developed. The evidence is unequivocal. Real-world data from countries with high HPV vaccination rates (Australia, UK, Sweden) show dramatic reductions in CIN 2/3 (precancerous changes) and cervical cancer rates in vaccinated cohorts. Australia is on track to be the first country in the world to effectively eliminate cervical cancer as a public health problem. Gardasil 9 prevents infection with HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 — collectively responsible for approximately 90% of cervical cancers. Cervarix covers types 16 and 18 (70% of cervical cancers). CERVAVAC (India's own vaccine) covers types 6, 11, 16, and 18. Vaccination is most effective when given before first sexual contact (ages 9–14) — but is beneficial at any age up to 45 for HPV types not yet acquired. Importantly: even vaccinated women must continue regular Pap smear screening — the vaccine does not cover all HPV types, and some cervical cancers arise from non-vaccine types.
No — post-coital bleeding (PCB) is not always cervical cancer. The most common cause of PCB in young women of reproductive age is cervical ectropion — a completely benign condition in which the inner glandular cells of the cervical canal extend onto the outer surface of the cervix, forming a red, velvety area that bleeds easily on contact during intercourse. Other common benign causes include: cervicitis (cervical infection — particularly chlamydia, which is very common and often asymptomatic), cervical polyps, and vaginal atrophy in post-menopausal women. However — PCB is the most characteristic early symptom of cervical cancer. This is not a contradiction. PCB is common AND it can indicate cancer. The clinical obligation is to take EVERY episode of PCB seriously, perform a speculum examination of the cervix, take a Pap smear, and perform STI screening. If a visible cervical lesion is present — biopsy immediately, do not wait for the smear result. The contraceptive pill does NOT cause PCB. If a woman on the OCP reports PCB, a cervical cause must be found — it cannot be attributed to the pill.
No — CIN 3 is NOT cancer. CIN stands for Cervical Intraepithelial Neoplasia — the precancerous change of the cervical epithelium caused by persistent HPV infection. CIN 3 (also called carcinoma in situ) means the full thickness of the surface epithelium is abnormal, but the basement membrane is intact — the abnormal cells have NOT invaded the underlying tissue. CIN 3 is a pre-cancerous change that will progress to invasive cancer if left untreated — over a period of months to years. This is precisely why it is detected by Pap smear and colposcopy before it becomes cancer. Treatment with LLETZ (Large Loop Excision of the Transformation Zone) — a 15-minute outpatient procedure under local anaesthetic — removes the abnormal area with cure rates exceeding 95%. After LLETZ for CIN 3, surveillance smears are required at 6 months, 12 months, then 3-yearly for 10 years, to ensure the CIN has been completely treated and does not recur. CIN 3 with clear margins after LLETZ represents a cured pre-cancerous condition — not a cancer diagnosis.
Yes — you should seek urgent evaluation, despite the recent normal Pap smear. This situation is actually one of the classic diagnostic pitfalls in cervical cancer: a woman has a normal smear, is falsely reassured, and then develops new symptoms that are attributed to the benign explanation without further investigation. A normal Pap smear does not exclude cervical cancer for several reasons: Pap smear sensitivity is approximately 70–80% for CIN 2+ — it can miss abnormalities, particularly in the endocervical canal. A cancer can develop rapidly in the interval between smears. The Pap smear tests the surface cells — a visible cervical lesion that is already cancerous may not shed diagnostic cells onto the sampling brush. The correct action when a woman develops new PCB — regardless of recent smear result — is: a thorough speculum examination of the cervix. If a lesion is visible: biopsy immediately. If no visible lesion: repeat Pap smear + colposcopy referral. A normal smear from 12 months ago is not reassurance for a woman with new, unexplained PCB today.
The recommended age for beginning cervical screening varies slightly between national guidelines, but the broad consensus for Indian women is as follows: Pap smear alone (cytology only): Begin at age 21 (or within 3 years of first sexual activity, whichever comes first). Repeat every 3 years for ages 21–30. Pap smear + HPV co-testing: Begin at age 25–30. Repeat every 5 years (most sensitive and specific strategy). If co-test is negative (normal smear + HPV negative), 5-year interval is safe. For Indian women specifically: given the high burden of cervical cancer and low screening rates, the National Cancer Grid of India recommends annual pelvic examination and Pap smear screening for all sexually active women, particularly in high-risk settings. The most recent national guidelines support HPV primary testing as the most effective screening strategy when resources allow. Continue until age 65 (or 70 in some guidelines) — after which screening can be discontinued if the last 3 smears have been normal.
Yes — ages 9–14 represent the optimal window for HPV vaccination, and a 10-year-old daughter is in the ideal age group. Vaccination at this age produces a stronger immune response than vaccination at older ages — and the 2-dose schedule (rather than 3 doses for older girls) is sufficient, making it both more convenient and more cost-effective. Key points for parents: The vaccine protects against cancer — not sexual activity. It is a cancer-prevention vaccine, not a licence for sexual activity. Countries that have vaccinated girls at this age have seen dramatic reductions in precancerous cervical changes in young women. Vaccination at ages 9–14 provides maximum protection because it is given before HPV exposure (before sexual debut). Once a person acquires HPV, the vaccine cannot eliminate existing infection — it only prevents new types from being acquired. All three vaccines approved in India (Gardasil 9, Cervarix, CERVAVAC) are safe, well-tolerated, and effective. CERVAVAC — India's own vaccine — offers an affordable option that makes vaccination accessible to a much wider population. After vaccination, regular Pap smear screening must still be performed from the appropriate age.
Yes — cervical cancer can absolutely be cured, particularly when detected at an early stage: Stage IA1 (microscopic cancer, <3mm invasion): cure rate approaches 99–100% with cone biopsy or simple hysterectomy. Stage IB1 (small visible tumour, confined to cervix): 5-year survival 88–95% with radical hysterectomy or radiotherapy. Stage IIB (parametrial involvement): 5-year survival 58–65% with concurrent chemoradiotherapy. Even for locally advanced disease (Stage IIIB), concurrent chemoradiotherapy achieves meaningful long-term cure in a significant proportion of patients — particularly when delivered at specialist centres with full brachytherapy capability. The truly critical determinant of outcome is the stage at which cancer is diagnosed — which is entirely within the patient's ability to influence, through Pap smear screening and prompt response to symptoms like post-coital bleeding. A woman who is screened regularly and reports PCB promptly has every chance of being diagnosed at Stage I — when cure is the expectation, not the hope. At Shree Hospitals, Dr. Jay Mehta and the team are committed to maximising cure rates through optimal surgical cytoreduction and adherence to international treatment guidelines.
It is absolutely not too late — and in fact, beginning cervical screening now is one of the most important health investments you can make. Studies show that women who have never been screened are at far higher risk of cervical cancer, particularly invasive cancer, than those who are regularly screened. Beginning screening at 40 — even for the first time — significantly reduces your remaining lifetime risk. At your first screening visit, a Pap smear and HPV co-test should be performed. If both are negative, your risk is very low and you can follow the routine 5-year recall schedule. If either is abnormal, the result will guide the appropriate next step. You should also consider HPV vaccination. Gardasil 9 is approved for women up to age 45 and provides protection against HPV types not yet acquired. While the benefit is somewhat reduced compared to vaccination at age 9–14, it is still meaningful for many women and is recommended as a shared decision with your doctor. Please call +91-9920914115 to book a cervical screening appointment with Dr. Jay Mehta's team at Shree Hospitals. A Pap smear + HPV co-test takes less than 10 minutes. It could save your life.
A Pap smear (cervical cytology test) is a screening test — it collects cells from the surface of the cervix and sends them to a laboratory where a specialist examines them under a microscope for abnormal changes. It is quick (2–3 minutes), performed in the outpatient clinic, and requires no anaesthetic. It tests ALL the cervical cells indiscriminately — it cannot tell you exactly where an abnormality is located. A colposcopy is a diagnostic test — performed when the Pap smear is abnormal or when a cervical lesion needs to be assessed. It uses a colposcope (a large, lighted magnifying instrument positioned outside the vagina) to magnify the cervix 10–40 times. The cervix is painted with acetic acid (which makes abnormal areas turn white) and Lugol's iodine. Abnormal areas are biopsied under direct visualisation — providing a histological (tissue) diagnosis. The pathway is: abnormal Pap smear → colposcopy → biopsy → diagnosis → treatment. Pap smear is the sieve; colposcopy is the net. A colposcopy is performed at Shree Hospitals by Dr. Jay Mehta and the team, typically as a 20-minute outpatient procedure. Same-visit LLETZ (treatment of CIN 2–3) is available — meaning diagnosis and treatment can be completed in a single consultation.
LLETZ (Large Loop Excision of the Transformation Zone) is the standard outpatient surgical treatment for CIN 2 and CIN 3. Here is exactly what to expect: During the procedure: A speculum is inserted (like a smear test). Local anaesthetic injection is given to the cervix — mild stinging for 10–20 seconds. The abnormal area is removed using a wire loop heated with electrical current — the procedure itself takes 5–10 minutes and most women feel only mild pressure or cramping. Immediately after: A chemical (Monsel's paste) or electrocautery is applied to stop bleeding. Some women feel lightheaded — this is normal and settles quickly. In the days/weeks after: Brown or dark discharge for 1–3 weeks (from the cauterising paste). Light bleeding or spotting for up to 4 weeks — normal. Mild period-like cramping for 1–2 days. Avoid sexual intercourse, tampons, and swimming for 4 weeks to allow healing and reduce infection risk. When to seek help: Heavy bleeding (soaking a pad in under an hour), signs of infection (offensive discharge, high fever), or severe pain should prompt same-day medical attention. Follow-up: Pap smear at 6 months (test of cure). If normal, annual smear for 2 years, then 3-yearly for the remaining 10-year surveillance period.
This depends critically on the stage of the cancer and the type of surgery recommended. There are three different scenarios: LLETZ for CIN (pre-cancerous change — not cancer): A single LLETZ has minimal impact on fertility. Multiple LLETZ procedures or deep cone biopsy may weaken the cervix (cervical incompetence), increasing risk of late miscarriage or premature birth in future pregnancies. Discuss this explicitly with your surgeon before the procedure. Early invasive cervical cancer in a young woman (Stage IA2–IB1 ≤2cm): Radical trachelectomy — surgical removal of the cervix with preservation of the uterus — allows future pregnancy. This fertility-preserving procedure is performed at Shree Hospitals by Dr. Jay Mehta for appropriately selected patients. Successful pregnancies have been documented after trachelectomy, though there is an increased risk of premature birth. Standard radical hysterectomy (Stage IB1–IIA or larger): The uterus is removed — future pregnancy is not possible. If preserving fertility matters to you, please tell Dr. Mehta explicitly at the very first consultation — this changes the surgical planning. For women who have not yet completed their family, fertility preservation options should always be explored with a Gynecologic Oncologist before deciding on treatment.
Concurrent chemoradiotherapy (CCRT) is the gold-standard treatment for locally advanced cervical cancer (Stage IIB–IVA) per NCCN, ESGO, and WHO guidelines. It involves two treatments given simultaneously: External beam pelvic radiotherapy (EBRT): High-energy radiation beams are directed at the pelvis from outside the body — targeting the cervical tumour and the pelvic lymph nodes. Given in daily sessions (Monday to Friday) over 5 weeks. Concurrent weekly cisplatin: A low-dose chemotherapy drug (40mg/m² intravenously) given once a week during the radiotherapy course (5 weekly doses). Cisplatin acts as a radio-sensitiser — making the tumour cells more vulnerable to the radiation. Intracavitary brachytherapy: After EBRT is completed, a specialised applicator is placed inside the vagina and cervix, allowing a very high dose of radiation to be delivered directly to the cervical tumour from inside. Typically 3–5 sessions given over 2–3 weeks. This final boost significantly improves local tumour control. The entire CCRT treatment takes 7–8 weeks. Common side effects include: fatigue, bowel frequency (radiation proctitis), urinary frequency, and nausea during weekly cisplatin. Most side effects settle after treatment ends.
A positive HPV test on your smear means that a high-risk Human Papillomavirus type has been detected on your cervix. This does NOT mean you have cervical cancer — and it does NOT mean you definitely will get cancer. HPV is an extremely common sexually transmitted virus. Research shows that approximately 80% of sexually active people acquire HPV infection at some point in their lives. In most cases — particularly in younger women — the immune system clears the virus completely within 12–24 months without any treatment and without causing any harm. Only a small minority of HPV infections persist (do not clear) and cause precancerous changes (CIN) — and of those, an even smaller proportion progress to invasive cancer over a period of 10–15 years. This lengthy timeline is precisely why screening is so effective — there is a wide window in which precancerous changes can be detected and treated. What happens next depends on your specific HPV type and your smear cell result: HPV 16 or 18 with any cytology → colposcopy. Other high-risk HPV types with normal cytology → repeat co-test in 12 months. HPV positive with LSIL or HSIL → colposcopy urgently. Please attend your recommended follow-up appointment.
Women travel from across India — Maharashtra, Gujarat, Rajasthan, Madhya Pradesh, Chhattisgarh, Andhra Pradesh, Karnataka, and many other states — to Shree Hospitals for cervical cancer treatment for several specific reasons: Dr. Jay Mehta's surgical expertise in Gynecologic Oncology: The quality of radical hysterectomy — particularly the nerve-sparing technique that reduces bladder and bowel complications — requires dedicated subspecialty training. Dr. Mehta's experience performing robotic-assisted and laparoscopic radical hysterectomy means patients benefit from minimal incisions, faster recovery, and equivalent oncological outcomes to open surgery. Fertility-preserving surgery: Radical trachelectomy (preserving the uterus in young women with early cervical cancer) is available at Shree Hospitals — a highly specialised procedure not available at most centres. Complete treatment infrastructure: Shree Hospitals provides the complete CCRT package (external beam radiotherapy, brachytherapy, concurrent cisplatin chemotherapy) under one roof. MDT care: Genuine multidisciplinary decision-making by oncosurgeon, medical oncologist, radiation oncologist, radiologist, pathologist — coordinated by a single point of contact. For women from other states, online consultations allow initial case review before committing to travel — and telemedicine follow-up reduces the need to return to Mumbai for every post-treatment visit.
🚨 Cervical Cancer Warning Signs — See a Specialist TODAY
Do not wait — any of these signs requires urgent specialist evaluation. Share this section with every woman you know — on WhatsApp, social media, and in conversation.
- Bleeding after sexual intercourse (post-coital bleeding) — at any age, this requires urgent cervical examination. Do not attribute it to the pill, friction, or a recent normal smear.
- Bleeding between periods (intermenstrual bleeding) — any new, unexplained bleeding between periods
- Any vaginal bleeding after menopause — even a small amount or staining requires urgent evaluation
- Unusual or persistent watery, blood-tinged, or foul-smelling vaginal discharge — particularly if it persists despite antibiotic treatment
- Pelvic pain or lower back pain that is new, persistent, or worsening
- Pain during sexual intercourse (dyspareunia) that is new or getting worse — particularly when combined with bleeding
- Leg swelling (especially one-sided) combined with any of the above — suggests lymph node involvement
- Difficulty passing urine or blood in the urine combined with pelvic pain
- You have not had a Pap smear in more than 3–5 years — this is a preventive emergency, particularly if you have ever been sexually active
- You have been told you have an abnormal Pap smear result and have not yet had a follow-up colposcopy — act today, not tomorrow
Dr. Jay Mehta & Team | Department of Gynecologic Oncology | Shree Hospitals, Mumbai
📞 +91-9920914115 | Toll-Free: 18002684000
💻 Online consultations available for all India — Pap smear result review, colposcopy findings, biopsy reports, and MRI staging without immediate travel to Mumbai
Cervical cancer is preventable. Detected early — it is curable. Act today.
📞 +91-9920914115 | Toll-Free: 18002684000
💻 Online consultations available for all India — Pap smear result review, colposcopy findings, biopsy reports, and MRI staging without immediate travel to Mumbai
Cervical cancer is preventable. Detected early — it is curable. Act today.
Glossary — Every Cervical Cancer Term Explained
- HPV (Human Papillomavirus)
- A common sexually transmitted virus responsible for 99.7% of all cervical cancers. Over 200 HPV types exist; approximately 14 are classified as 'high-risk' (oncogenic). HPV 16 and 18 alone cause 70% of cervical cancers. Most infections clear spontaneously within 12–24 months; only persistent high-risk HPV infection leads to cancer over 10–15 years.
- Post-Coital Bleeding (PCB)
- Vaginal bleeding that occurs during or immediately after sexual intercourse. The most characteristic early symptom of cervical cancer — present in approximately 70–80% of women at diagnosis. Every episode of PCB requires urgent cervical examination and Pap smear, regardless of age, contraceptive use, or recent smear result.
- Pap Smear (Cervical Cytology Test)
- A screening test that collects cells from the surface of the cervix — specifically from the transformation zone — and sends them to a laboratory where a specialist examines them under a microscope for abnormal changes. Quick (2–3 minutes), performed in the outpatient clinic, requires no anaesthetic. Recommended every 3 years (cytology alone) or every 5 years (cytology + HPV co-test) from age 21.
- HPV Co-testing
- Performing an HPV test simultaneously with the Pap smear using the same sample. The most sensitive cervical cancer screening strategy. A normal Pap smear + HPV negative result provides the best possible reassurance and allows a 5-year screening interval. HPV 16 or HPV 18 positive on co-testing triggers colposcopy referral even if cytology is normal.
- Colposcopy
- A diagnostic examination of the cervix performed when a Pap smear is abnormal or when a cervical lesion needs direct assessment. A colposcope (large, lighted magnifying instrument) is positioned outside the vagina and provides a magnified (×10–40) view of the cervical surface. The cervix is painted with acetic acid (making abnormal areas appear white) and Lugol's iodine. Abnormal areas are biopsied under direct visualisation.
- CIN (Cervical Intraepithelial Neoplasia)
- Pre-cancerous change of the cervical epithelium caused by persistent HPV infection. CIN 1: mild dysplasia (low-grade) — outer one-third of epithelium involved. CIN 2: moderate dysplasia — outer two-thirds of epithelium involved. CIN 3: severe dysplasia/carcinoma in situ — full-thickness epithelial dysplasia, but the basement membrane is intact (not yet invasive cancer). All grades of CIN are detectable by Pap smear and colposcopy, and all are treatable — CIN is NOT cancer.
- Transformation Zone
- The area on the cervix where the squamous epithelium of the outer cervix meets the glandular epithelium of the endocervical canal. This is the area where CIN and cervical cancer almost exclusively develop. The transformation zone is the target of the Pap smear sampling brush and the focus of colposcopy.
- LLETZ (Large Loop Excision of the Transformation Zone)
- The standard outpatient surgical treatment for CIN 2 and CIN 3. Performed under local anaesthetic in the colposcopy clinic. A wire loop heated with electrical current is used to remove the abnormal transformation zone. Takes 5–10 minutes. Cure rates exceed 95% for CIN 2–3 when clear surgical margins are achieved. Surveillance smears required at 6 months, 12 months, then 3-yearly for 10 years post-LLETZ.
- Cervical Ectropion (Cervical Erosion)
- A completely benign condition in which the glandular cells of the endocervical canal extend onto the outer surface of the cervix, forming a red, velvety area. Very common in young women, pregnant women, and women on the contraceptive pill. The term 'erosion' is a misnomer — no damage has occurred. Can bleed easily on contact, causing post-coital bleeding that must be distinguished from cervical cancer by Pap smear and colposcopy.
- Radical Hysterectomy
- Surgical removal of the uterus, cervix, upper vagina, and the parametria (supporting ligaments of the cervix containing lymphatic channels), combined with pelvic lymph node dissection. The standard surgical treatment for Stage IA2–IB2 cervical cancer. Performed laparoscopically, robotically, or by open surgery — with equivalent oncological outcomes when performed by an experienced Gynecologic Oncologist.
- Radical Trachelectomy
- A fertility-preserving surgical alternative to radical hysterectomy for young women with early cervical cancer (Stage IA2–IB1 ≤2cm). The cervix is surgically removed while the uterus is preserved and reconnected to the upper vagina, allowing future pregnancy. Performed laparoscopically or with robotic assistance at specialist centres including Shree Hospitals. Successful pregnancies after radical trachelectomy have been documented in the medical literature.
- CCRT (Concurrent Chemoradiotherapy)
- The gold-standard treatment for locally advanced cervical cancer (Stage IIB–IVA). Combines external beam pelvic radiotherapy (EBRT, given daily over 5 weeks) with weekly intravenous cisplatin chemotherapy (which acts as a radio-sensitiser), followed by intracavitary brachytherapy (internal radiotherapy delivered directly to the cervical tumour). The entire CCRT treatment takes 7–8 weeks.
- Brachytherapy (Intracavitary Radiotherapy)
- A specialised form of internal radiotherapy delivered through applicators placed inside the vagina and cervix, allowing a very high dose of radiation to be delivered directly to the cervical tumour. Provides the highest radiation dose to the tumour while sparing adjacent bladder and rectum. An essential component of CCRT for locally advanced cervical cancer — significantly improves local control and survival rates compared to external beam radiotherapy alone.
- FIGO Staging
- The International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer — classifying the disease into stages I–IV based on the extent of tumour spread. Stage I: confined to the cervix. Stage II: beyond cervix but not to pelvic sidewall or lower third of vagina. Stage III: to pelvic sidewall/lower third of vagina or hydronephrosis. Stage IV: involvement of bladder, rectum, or distant metastases.
- CERVAVAC
- India's first indigenously developed HPV vaccine — a 4-valent vaccine against HPV types 6, 11, 16, and 18. Developed and manufactured by the Serum Institute of India (SII). Available at approximately ₹2,000–2,500 per dose — significantly more affordable than imported HPV vaccines. Approved for girls aged 9–26 in India. The most cost-accessible HPV vaccination option in India, making cervical cancer prevention accessible to a much wider population.
- AIS (Adenocarcinoma In Situ)
- Pre-invasive glandular cancer of the endocervical canal — the glandular precursor to cervical adenocarcinoma. Often invisible on colposcopy because it is located in the endocervical canal beyond direct visualisation. Detected by Pap smear (as AGC or AIS on cytology) or by directed biopsy. Requires cone biopsy (not just LLETZ) for complete assessment. Hysterectomy strongly recommended for women who have completed their family — AIS has a 'skip lesion' nature, meaning disease may exist above the visible margin.
Medical Disclaimer — IMPORTANT: PLEASE READ. This guide has been prepared by the Department of Gynecologic Oncology at Shree Hospitals for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. The vaccine costs listed are approximate at the time of writing and are subject to change. Actual costs vary by centre, city, and time. Please verify current pricing directly with Shree Hospitals or your local healthcare provider before scheduling vaccination. Vaccine schedules and eligibility criteria are based on current ACIP, IAP, FOGSI, and WHO guidelines and are subject to revision. Always confirm the recommended schedule with your doctor at the time of vaccination. Pap smear result interpretations, CIN classifications, staging criteria, and treatment protocols described are based on current international evidence. Individual patient management must be decided by a qualified medical professional following thorough clinical evaluation. In an emergency, call your nearest hospital or dial 112.
© Department of Gynecologic Oncology, Shree Hospitals. All rights reserved. Content may not be reproduced without written permission.
© Department of Gynecologic Oncology, Shree Hospitals. All rights reserved. Content may not be reproduced without written permission.
